Incannex Healthcare Inc. (Nasdaq: IXHL) announced that participant screening has begun in its DReAMzz Phase 2 dose confirmation study evaluating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE